

Yong Lu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2649334/publications.pdf>

Version: 2024-02-01

32
papers

2,197
citations

430874

18
h-index

477307

29
g-index

33
all docs

33
docs citations

33
times ranked

3216
citing authors

#	ARTICLE	IF	CITATIONS
1	OUP accepted manuscript. Briefings in Bioinformatics, 2022, , .	6.5	0
2	Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion. Nature Nanotechnology, 2022, 17, 206-216.	31.5	46
3	SIRP β -expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling. Journal of Clinical Investigation, 2022, 132, .	8.2	20
4	VOC-alarm: mutation-based prediction of SARS-CoV-2 variants of concern. Bioinformatics, 2022, 38, 3549-3556.	4.1	4
5	Immuno-reactive Cancer Organoid Models to Examine Microbiome Metabolite Effects on Immune Checkpoint Blockade Efficacy. FASEB Journal, 2021, 35, .	0.5	0
6	Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells. Cancer Cell, 2021, 39, 1610-1622.e9.	16.8	25
7	Speed and Location Both Matter: Antigen Stimulus Dynamics Controls CAR-T Cell Response. Frontiers in Immunology, 2021, 12, 748768.	4.8	4
8	Elimination of acquired resistance to PD-1 blockade via the concurrent depletion of tumour cells and immunosuppressive cells. Nature Biomedical Engineering, 2021, 5, 1306-1319.	22.5	21
9	Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9. Nature Communications, 2020, 11, 5902.	12.8	55
10	Targeting the IL-9 pathway in cancer immunotherapy. Human Vaccines and Immunotherapeutics, 2020, 16, 2333-2340.	3.3	26
11	An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases. Nature Communications, 2019, 10, 5108.	12.8	148
12	Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment. Cell Metabolism, 2019, 30, 143-156.e5.	16.2	460
13	Dissecting intratumoral myeloid cell plasticity by single cell RNA-seq. Cancer Medicine, 2019, 8, 3072-3085.	2.8	103
14	IL-4 together with IL-1 β induces antitumor Th9 cell differentiation in the absence of TGF- β signaling. Nature Communications, 2019, 10, 1376.	12.8	74
15	miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. Journal of Hematology and Oncology, 2018, 11, 58.	17.0	98
16	Cholesterol negatively regulates IL-9-producing CD8+ T cell differentiation and antitumor activity. Journal of Experimental Medicine, 2018, 215, 1555-1569.	8.5	98
17	Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors. Cancer Cell, 2018, 33, 1048-1060.e7.	16.8	117
18	Foxo1 and Foxp1 play opposing roles in regulating the differentiation and antitumor activity of T _H 9 cells programmed by IL-7. Science Signaling, 2017, 10, .	3.6	47

#	ARTICLE	IF	CITATIONS
19	Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw131.	6.3	37
20	Dectin-1-activated dendritic cells: A potent Th9 cell inducer for tumor immunotherapy. <i>Oncolmmunology</i> , 2016, 5, e1238558.	4.6	15
21	Dectin-1-activated dendritic cells trigger potent antitumour immunity through the induction of Th9 cells. <i>Nature Communications</i> , 2016, 7, 12368.	12.8	103
22	Could B7-H4 serve as a target to activate anti-cancer immunity?. <i>International Immunopharmacology</i> , 2016, 38, 97-103.	3.8	15
23	Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma. <i>Oncotarget</i> , 2015, 6, 24218-24229.	1.8	66
24	Anti- β 2-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. <i>Oncotarget</i> , 2015, 6, 8567-8578.	1.8	26
25	Tumor-specific IL-9 ⁺ producing CD8 ⁺ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 2265-2270.	7.1	116
26	Anticancer Tc9 cells: Long-lived tumor-killing T cells for adoptive therapy. <i>Oncolmmunology</i> , 2014, 3, e28542.	4.6	11
27	p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression. <i>Nature Communications</i> , 2014, 5, 4229.	12.8	49
28	A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. <i>Blood</i> , 2014, 124, 2061-2071.	1.4	87
29	Utilizing TH9 cells as a novel therapeutic strategy for malignancies. <i>Oncolmmunology</i> , 2013, 2, e23084.	4.6	17
30	Anti- β 2 Microglobulin Monoclonal Antibodies Overcome Bortezomib-Induced Drug Resistance In Multiple Myeloma By Inhibition Of Autophagy. <i>Blood</i> , 2013, 122, 929-929.	1.4	0
31	Th9 cells promote antitumor immune responses in vivo. <i>Journal of Clinical Investigation</i> , 2012, 122, 4160-4171.	8.2	303
32	Expression of B7-H1 in Mantle Cell Lymphoma Leads to Inhibition of T Cell Response to Tumor Cells. <i>Blood</i> , 2011, 118, 2643-2643.	1.4	0